Moxifloxacin as an Alternative or Additive Therapy for Treatment of Pulmonary Tuberculosis

Fouad, Mohamed Hassan Ahmed; Gallagher, Jason C

doi:10.1345/aph.1q299

Cited by 19 publications

(9 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, p- aminosalicylic acid slows down the acetylation of isoniazid in the organism, and provides a stable concentration of amantadine hydrochloride in the blood, which decreases the toxicity of isoniazid in the liver ( 11 ). Rifabutin is spiro derivative of piperidine and rifamycin; its activity against Mycobacterium tuberculosis activity is 4-fold stronger than that of the commonly clinically used drug rifampicin, and it is active against rifampicin-resistant tuberculosis ( 12 , 13 ). Amikacin, pasiniazid, pyrazinamide and propylthiouracil isonicotinoyl amine are classical anti-tuberculosis drugs.…”

Section: Discussionmentioning

confidence: 99%

Super-compact treatment with a high dose of moxifloxacin in patients with drug-resistant tuberculosis and its resistance mechanisms

Wang

Zhang

Guo

et al. 2015

Experimental and Therapeutic Medicine

View full text Add to dashboard Cite

The aim of this study was to investigate the curative effect and resistance mechanisms of high-dose moxifloxacin in the short-term treatment of multidrug-resistant tuberculosis. A total of 92 patients with multidrug-resistant tuberculosis were randomly selected and divided into groups A and B (n=46 per group). The two groups received moxifloxacin treatment with the same dose in total. Group A received a short course of treatment with moxifloxacin (0.6 g/day for 6 months), whereas group B received normal moxifloxacin treatment (0.4 g/day for 9 months). Sputum negative conversion, foci absorption, cavity closure and adverse reactions in the two groups were observed, and the drug resistance mechanism of tuberculosis to moxifloxacin treatment was investigated. Following the treatment, the curative rate of group A was 82.61%, and the curative rate of group B was 84.78%; there was no statistically significant difference between the two groups (P>0.05). The rates of sputum negative conversion, foci absorption and cavity closure were not significantly different between the two groups (P>0.05). However, the rates of reduction in peripheral white blood cell counts, liver function damage and adverse reactions, including symptoms affecting the gastrointestinal and nervous systems, were significantly lower in group A than in group B (P<0.05). The expression levels of the antigen-presenting functional molecules CD80 and CD40 on the surfaces of mononuclear cells were higher in group A than in group B (P<0.05), whereas the difference in HLA-DR expression between groups A and B was not significant (P>0.05). In conclusion, short-term treatment with a high dose of moxifloxacin is effective for multidrug-resistant tuberculosis, and its advantages are a reduction in the incidence of drug-associated adverse reactions and a lack of drug resistance.

show abstract

Section: Discussionmentioning

confidence: 99%

Super-compact treatment with a high dose of moxifloxacin in patients with drug-resistant tuberculosis and its resistance mechanisms

Wang

Zhang

Guo

et al. 2015

Experimental and Therapeutic Medicine

View full text Add to dashboard Cite

show abstract

“…A previous study revealed that a combination of moxifloxacin, clarithromycin, and ethambutol showed therapeutic efficacy against M. avium 11 . Moreover, moxifloxacin is more effective against mycobacterial disease than older quinolone 1 12 . However, although moxifloxacin has a favorable therapeutic effect against M. avium , it is unclear whether it also has a favorable effect against M. malmoense because no studies have examined this issue.…”

Section: Discussionmentioning

confidence: 99%

Lung Disease Caused byMycobacterium malmoensein an Immunocompetent Patient

et al. 2015

View full text Add to dashboard Cite

show abstract

“…An animal study showed comparable activity of 400 mg of gatifloxacin, 400 mg of moxifloxacin and 1000 mg of levofloxacin, with the latter being slightly more active; at that elevated dose, ciprofloxacin was more active than ofloxacin [16,17]. Phase 2 clinical trials demonstrated that moxifloxacin versus ethambutol, isoniazid versus moxifloxacin and gatifloxacin versus ethambutol all showed a tendency to more rapid sterilisation at 8 weeks [18].…”

Section: Tuberculosismentioning

confidence: 99%